中药辅助治疗2型糖尿病合并颈动脉粥样硬化的疗效与安全性:27项随机对照试验的更新meta分析
该更新meta分析纳入27项随机对照试验共2638例2型糖尿病合并颈动脉粥样硬化患者,系统评价口服中药联合西药对比单用西药的疗效与安全性。结果显示联合中药在改善颈动脉内膜中层厚度、斑块Crouse评分、糖脂代谢及胰岛素抵抗方面可能更具优势,且未观察到严重不良事件,但受纳入研究质量与异质性限制,证据确定性仍有限。
要点
- 中药联合西药较单用西药可进一步降低颈动脉内膜中层厚度与斑块Crouse评分。
- 联合中药可改善糖脂代谢、胰岛素抵抗及胰岛β细胞功能,且未报告严重不良事件。
- 受研究质量与异质性限制,中药疗效与安全性证据仍不确定,需更多高质量研究。
核心结论
- 在2型糖尿病合并颈动脉粥样硬化患者中,联合中药可能较单用西药更具优势,可进一步降低颈动脉内膜中层厚度和斑块Crouse评分,调节糖脂代谢,改善胰岛素抵抗并增强胰岛β细胞功能,且相对安全。
研究设计与样本
- 本研究为更新meta分析,已在PROSPERO注册(CRD42022346274),检索中英文数据库自建库至2022年7月16日。
- 纳入27项口服中药治疗2型糖尿病合并颈动脉粥样硬化患者的随机对照试验,共涉及2638例患者。
- 采用Cochrane手册偏倚风险评估工具评价文献质量,使用Review Manager 5.4和Stata 16.0进行meta分析,通过meta回归或亚组分析探索异质性来源,采用漏斗图和Egger检验评估发表偏倚,并使用GRADE评估证据质量。
主要发现
- 与单用西药相比,加用中药在改善颈动脉内膜中层厚度方面更优:MD=-0.11mm,95%CI:-0.15至-0.07,p<0.01。
- 加用中药在改善颈动脉斑块Crouse评分方面更优:MD=-1.21,95%CI:-1.35至-1.07,p<0.01。
- 加用中药在改善总胆固醇(MD=-0.34 mmol/L,95%CI:-0.54至-0.14,p<0.01)、甘油三酯(MD=-0.26 mmol/L,95%CI:-0.37至-0.15,p<0.01)、低密度脂蛋白胆固醇(MD=-0.36 mmol/L,95%CI:-0.47至-0.25,p<0.01)和高密度脂蛋白胆固醇(MD=0.22 mmol/L,95%CI:0.13至0.30,p<0.01)方面更优。
- 加用中药在改善糖化血红蛋白(MD=-0.36%,95%CI:-0.51至-0.21,p<0.01)、空腹血糖(MD=-0.33 mmol/L,95%CI:-0.50至-0.16,p<0.01)、餐后2小时血糖(MD=-0.52 mmol/L,95%CI:-0.95至-0.09,p<0.01)、HOMA-IR(SMD=-0.88,95%CI:-1.36至-0.41,p<0.01)和HOMA-β(MD=0.80,95%CI:0.51至1.09,p<0.01)方面更优。
- 由于纳入研究数量少,中药对一氧化氮、内皮素-1、收缩期峰值流速和阻力指数的改善作用尚不明确;未观察到严重不良事件。
关键数值与推荐
- 与单用西药相比,加用中药改善颈动脉内膜中层厚度的MD=-0.11mm(95%CI:-0.15至-0.07,p<0.01)。
- 与单用西药相比,加用中药改善颈动脉斑块Crouse评分的MD=-1.21(95%CI:-1.35至-1.07,p<0.01)。
- 与单用西药相比,加用中药改善糖化血红蛋白的MD=-0.36%(95%CI:-0.51至-0.21,p<0.01),改善空腹血糖的MD=-0.33 mmol/L(95%CI:-0.50至-0.16,p<0.01)。
- 与单用西药相比,加用中药改善总胆固醇的MD=-0.34 mmol/L(95%CI:-0.54至-0.14,p<0.01),改善甘油三酯的MD=-0.26 mmol/L(95%CI:-0.37至-0.15,p<0.01)。
- 与单用西药相比,加用中药改善HOMA-IR的SMD=-0.88(95%CI:-1.36至-0.41,p<0.01),改善HOMA-β的MD=0.80(95%CI:0.51至1.09,p<0.01)。
临床怎么用
- 对于2型糖尿病合并颈动脉粥样硬化患者,在规范西药治疗基础上可考虑联合口服中药,以期进一步改善颈动脉斑块、糖脂代谢及胰岛功能。
- 联合中药时需关注患者个体化辨证与安全性监测,尤其应结合中药成分与患者肝肾功能等情况进行评估。
- 临床决策应认识到当前证据受纳入研究质量与异质性限制,中药疗效与安全性仍不确定,不宜据此替代或减停规范西药治疗。
局限性
- 纳入研究的质量和异质性限制了结论的可靠性,中药的疗效与安全性仍不确定。
- 由于纳入研究数量少,中药对一氧化氮、内皮素-1、收缩期峰值流速和阻力指数的改善作用尚不明确。
- 仍需更多高质量研究为中药的临床应用提供更可靠的证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Type 2 diabetes mellitus (T2DM) is a clinical metabolic syndrome characterized by persistent hyperglycemia. Patients with T2DM are more likely to have carotid atherosclerosis (CAS), which can lead to dizziness, amaurosis or even stroke. Chinese herbal medicine (CHM) has shown possible efficacy and safety in treating T2DM patients with CAS. However, the existing evidence was not robust enough and the results were out of date. Objective: This meta-analysis aimed to summarize the current evidence and systematically evaluate the effects of CHM on carotid plaque, glucose and lipid metabolism and vascular endothelial parameters in T2DM patients with CAS, providing a reference for subsequent research and clinical practice. Methods: This study was registered in PROSPERO as CRD42022346274. Both Chinese and English databases were searched from their inceptions to 16 July 2022. All retrieved studies were screened according to inclusion and exclusion criteria. Randomized controlled trials (RCTs) using oral CHM to treat T2DM patients with CAS were included. The literature quality was assessed using the risk of bias assessment tool in the Cochrane Handbook. Data extraction was conducted on the selected studies. Review Manager 5.4 and Stata 16.0 were used for meta-analysis. Sources of heterogeneity were explored by meta-regression or subgroup analysis. Funnel plot and Egger's test were used to assess publication bias and the evidence quality was assessed by Grading of Recommendations Assessment, Development and Evaluation (GRADE). Results: 27 eligible studies, involving 2638 patients, were included in this study. Compared with western medicine (WM) alone, the addition of CHM was significantly better in improving carotid intima-media thickness (CIMT) [mean difference (MD) = -0.11mm, 95% confidence interval (CI): -0.15 to -0.07, p < 0.01], carotid plaque Crouse score [MD = -1.21, 95%CI: -1.35 to -1.07, p < 0.01], total cholesterol (TC) [MD = -0.34 mmol/L, 95%CI: -0.54 to -0.14, p < 0.01], triglyceride (TG) [MD = -0.26 mmol/L, 95%CI: -0.37 to -0.15, p < 0.01], low-density lipoprotein cholesterol (LDL-C) [MD = -0.36 mmol/L, 95%CI: -0.47 to -0.25, p < 0.01], high-density lipoprotein cholesterol (HDL-C) [MD = 0.22 mmol/L, 95%CI: 0.13 to 0.30, p < 0.01], glycated hemoglobin (HbA1c) [MD = -0.36%, 95%CI: -0.51 to -0.21, p < 0.01], fasting blood glucose (FBG) [MD = -0.33 mmol/L, 95%CI: -0.50 to -0.16, p < 0.01], 2-h postprandial glucose (2hPG) [MD = -0.52 mmol/L, 95%CI: -0.95 to -0.09, p < 0.01], homeostasis model assessment of insulin resistance (HOMA-IR) [standardized mean difference (SMD) = -0.88, 95%CI: -1.36 to -0.41, p < 0.01] and homeostasis model assessment of beta-cell function (HOMA-β) [MD = 0.80, 95%CI: 0.51 to 1.09, p < 0.01]. Due to the small number of included studies, it is unclear whether CHM has an improving effect on nitric oxide (NO), endothelin-1 (ET-1), peak systolic velocity (PSV) and resistance index (RI). No serious adverse events were observed. Conclusion: Based on this meta-analysis, we found that in the treatment of T2DM patients with CAS, combined with CHM may have more advantages than WM alone, which can further reduce CIMT and carotid plaque Crouse score, regulate glucose and lipid metabolism, improve insulin resistance and enhance islet β-cell function. Meanwhile, CHM is relatively safe. However, limited by the quality and heterogeneity of included studies, the efficacy and safety of CHM remain uncertain. More high-quality studies are still needed to provide more reliable evidence for the clinical application of CHM. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42022346274.
引用
- Zhang Z, Leng Y, Chen Z, et al. The efficacy and safety of Chinese herbal medicine as an add-on therapy for type 2 diabetes mellitus patients with carotid atherosclerosis: An updated meta-analysis of 27 randomized controlled trials. Front Pharmacol. 2023. PMID: 37033624. doi:10.3389/fphar.2023.1091718
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。